시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
항체약물접합체 수탁제조 시장 규모, 점유율, 성장 분석 : 개발 단계별, 프로세스 컴포넌트별, 대상 적응증별, 항체 세대별, 항체 기원별, 지역별 - 산업별 예측(2025-2032년)
Antibody Drug Conjugates Contract Manufacturing Market Size, Share, and Growth Analysis, By Stage of Development, By Process Component, By Target Indication, By Antibody Generation, By Antibody Origin, By Region - Industry Forecast 2025-2032
상품코드 : 1831573
리서치사 : SkyQuest
발행일 : 2025년 09월
페이지 정보 : 영문 183 Pages
 라이선스 & 가격 (부가세 별도)
US $ 5,300 ￦ 7,611,000
PDF & Excel (Single User License) help
PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,200 ￦ 8,904,000
PDF & Excel (Multiple User License) help
PDF 및 Excel 보고서를 동일 사업장에서 2-5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,100 ￦ 10,197,000
PDF & Excel (Enterprise License) help
PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

세계의 항체약물접합체 수탁제조 시장 규모는 2023년에 86억 달러로 평가되어 예측 기간(2025-2032년)에 CAGR 12.1%로 성장하며, 2024년 96억 4,000만 달러에서 2032년까지 240억 4,000만 달러로 성장할 전망입니다.

시장 인사이트에 따르면 세계 항체 의약품 복합체(ADC) 위탁 생산 부문은 표적 암 치료에 대한 선호도 증가와 생물제제 연구개발에 대한 막대한 투자로 인해 크게 성장하고 있습니다. 전 세계에서 암 유병률이 증가하면서 정밀의료에 대한 수요가 증가하고 있으며, ADC는 주목할 만한 치료 옵션으로 자리매김하고 있습니다. 또한 ADC의 제조가 복잡하므로 바이오컨쥬게이션에 대한 전문 지식, 첨단 봉쇄, 분석 테스트 등이 필요하며, 이는 새로운 비즈니스 기회를 창출하고 있습니다. FDA, EMA 등 규제기관의 신속한 승인으로 인한 지원은 수요를 더욱 증가시킬 것입니다. 반대로 높은 제조 비용, 엄격한 규제 프레임워크, 전문 수탁제조기관(CMO)의 부족, 공급망 문제 등은 가까운 미래에 시장의 성장과 침투를 저해할 수 있습니다.

목차

서론

조사 방법

개요

시장 역학과 전망

주요 시장 인사이트

항체약물접합체 수탁제조 시장 규모 : 개발 단계별 & CAGR(2025-2032)

항체약물접합체 수탁제조 시장 규모 : 프로세스 컴포넌트별 & CAGR(2025-2032)

항체약물접합체 수탁제조 시장 규모 : 대상 적응증별 & CAGR(2025-2032)

항체약물접합체 수탁제조 시장 규모 : 항체 세대별 & CAGR(2025-2032)

항체약물접합체 수탁제조 시장 규모 : 항체 기원별 & CAGR(2025-2032)

항체약물접합체 수탁제조 시장 규모 : 링커의 유형별 & CAGR(2025-2032)

항체약물접합체 수탁제조 시장 규모 : 최종사용자별 & CAGR(2025-2032)

항체약물접합체 수탁제조 시장 규모 & CAGR(2025-2032)

경쟁 정보

주요 기업 개요

결론과 제안

KSA
영문 목차

영문목차

Global Antibody Drug Conjugates Contract Manufacturing Market size was valued at USD 8.6 billion in 2023 and is poised to grow from USD 9.64 billion in 2024 to USD 24.04 billion by 2032, growing at a CAGR of 12.1% during the forecast period (2025-2032).

Market insights indicate a significant uptick in the global antibody drug conjugates (ADCs) contract manufacturing sector, driven by the rising preference for targeted cancer therapies and substantial investments in biologics R&D. The increasing prevalence of cancer globally has fueled the demand for precision medicine, positioning ADCs as a notable treatment option. Moreover, the complexity involved in ADC manufacturing-requiring specialized bioconjugation expertise, advanced containment, and analytical testing-presents new business opportunities. Support from regulatory bodies, including the FDA and EMA, through expedited approvals enhances demand further. Conversely, challenges such as high manufacturing costs, stringent regulatory frameworks, a scarcity of specialized contract manufacturing organizations (CMOs), and supply chain issues may impede market growth and penetration in the near future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antibody Drug Conjugates Contract Manufacturing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antibody Drug Conjugates Contract Manufacturing Market Segments Analysis

Global Antibody Drug Conjugates Contract Manufacturing Market is segmented by Stage of Development, Process Component, Target Indication, Antibody Generation, Antibody Origin, Type of Linker, End User and region. Based on Stage of Development, the market is segmented into Phase I, Phase II and Phase III. Based on Process Component, the market is segmented into Antibody, HPAPI / Cytotoxic Payload, Conjugation / Linker and Fill / Finish. Based on Target Indication, the market is segmented into Solid Tumors, Hematological Tumors and Others. Based on Antibody Generation, the market is segmented into Second Generation, Third Generation, Fourth Generation and Next Generation. Based on Antibody Origin, the market is segmented into Humanized, Chimeric, Murine and Others. Based on Type of Linker, the market is segmented into Maleimide, SMCC, Tetrapeptide-based linker, Valine-citrulline and Others. Based on End User, the market is segmented into Pharmaceutical Companies, Biotechnology Companies - 30%, Academic & Research Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Antibody Drug Conjugates Contract Manufacturing Market

The expanding therapeutic applications of various antibody drug conjugates have prompted pharmaceutical and biotech companies to enhance their investments in research and development. As clinical trials advance, there is a heightened demand for manufacturing partners that can provide scalable and compliant production solutions. Furthermore, the rising number of approvals for antibody drug conjugates globally is anticipated to generate additional opportunities for contract manufacturing firms specializing in this sector, thereby driving growth and innovation within the Global Antibody Drug Conjugates Contract Manufacturing market. The overall landscape remains dynamic, reflecting the increasing importance of these advanced therapeutics.

Restraints in the Global Antibody Drug Conjugates Contract Manufacturing Market

The global market for antibody drug conjugates contract manufacturing faces several challenges that could impede its growth. The complexity of the design, development, and production processes necessitates specialized facilities capable of handling antibodies, cytotoxic drugs, and conjugation, leading to substantial capital investments. Additionally, the high costs associated with research and development, stemming from the rigorous preclinical and clinical testing required to demonstrate safety and efficacy, may act as a barrier to demand. Such financial strains could hinder the viability and expansion of the contract manufacturing sector within this niche pharmaceutical market.

Market Trends of the Global Antibody Drug Conjugates Contract Manufacturing Market

The Global Antibody Drug Conjugates Contract Manufacturing market is witnessing a robust trend towards strategic collaborations and capacity expansions among contract manufacturing organizations (CMOs). Companies in this sector are prioritizing the establishment of partnerships with pharmaceutical innovators to create secure supply chains and ensure dedicated manufacturing slots, thereby mitigating potential bottlenecks. Additionally, the ongoing demand for scalable and flexible manufacturing solutions is driving CMOs to enhance their operational capabilities. This focus on maximizing business scope and flexibility is expected to solidify the role of antibody drug conjugates in innovative therapeutics, shaping a dynamic landscape in the contract manufacturing market.

Table of Contents

Introduction

Research Methodology

Executive Summary

Market Dynamics & Outlook

Key Market Insights

Global Antibody Drug Conjugates Contract Manufacturing Market Size by Stage of Development & CAGR (2025-2032)

Global Antibody Drug Conjugates Contract Manufacturing Market Size by Process Component & CAGR (2025-2032)

Global Antibody Drug Conjugates Contract Manufacturing Market Size by Target Indication & CAGR (2025-2032)

Global Antibody Drug Conjugates Contract Manufacturing Market Size by Antibody Generation & CAGR (2025-2032)

Global Antibody Drug Conjugates Contract Manufacturing Market Size by Antibody Origin & CAGR (2025-2032)

Global Antibody Drug Conjugates Contract Manufacturing Market Size by Type of Linker & CAGR (2025-2032)

Global Antibody Drug Conjugates Contract Manufacturing Market Size by End User & CAGR (2025-2032)

Global Antibody Drug Conjugates Contract Manufacturing Market Size & CAGR (2025-2032)

Competitive Intelligence

Key Company Profiles

Conclusion & Recommendations

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기